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1Percutaneous coronary intervention has revolutionized the treatment of patients with flow limiting coronary artery 
disease. Balloon angioplasty without stenting had limited 
success because of a high incidence of acute vessel closure 
caused by dissection or elastic recoil, late vascular remodel-
ing, and neointimal proliferation.1–3 The introduction of bare 
metal stents improved procedural success and acute out-
comes1; however, the clinical outcomes remained affected 
by high risk of in-stent restenosis.4–6 The drug-eluting stents 
(DES) substantially reduced neointimal proliferation,5–7 but 
first-generation DES eluting sirolimus or paclitaxel from a 
durable polymer raised safety concerns about late and very 
late stent thrombosis possibly because of delayed endothe-
lialization by the antiproliferative drugs and chronic inflam-
mation or delayed hypersensitivity reaction caused by the 
polymers in these DES.8–11 The second-generation DES have 
newer antiproliferative drugs (including zotarolimus and 
everolimus) and biocompatible or biodegradable polymers 
Background—Newer-generation drug-eluting stents that release zotarolimus or everolimus have been shown to be superior 
to the first-generation drug-eluting stents. However, data comparing long-term safety and efficacy of zotarolimus- (ZES) 
and everolimus-eluting stents (EES) are limited. RESOLUTE all-comers (Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) trial compared these 2 stents 
and has shown that ZES was noninferior to EES at 12-month for the primary end point of target lesion failure. We report 
the secondary clinical outcomes at the final 5-year follow-up of this trial.
Methods and Results—RESOLUTE all-comer clinical study is a prospective, multicentre, randomized, 2-arm, open-label, 
noninferiority trial with minimal exclusion criteria. Patients (n=2292) were randomly assigned to treatment with either 
ZES (n=1140) or EES (n=1152). Patient-oriented composite end point (combination of all-cause mortality, myocardial 
infarction, and any revascularizations), device-oriented composite end point (combination of cardiac death, target 
vessel myocardial infarction, and clinically indicated target lesion revascularization), and major adverse cardiac events 
(combination of all-cause death, all myocardial infarction, emergent coronary bypass surgery, or clinically indicated 
target lesion revascularization) were analyzed at 5-year follow-up. The 2 groups were well-matched at baseline. Five-
year follow-up data were available for 98% patients. There were no differences in patient-oriented composite end point 
(ZES 35.3% versus EES 32.0%, P=0.11), device-oriented composite end point (ZES 17.0% versus EES 16.2%, P=0.61), 
major adverse cardiac events (ZES 21.9% versus EES 21.6%, P=0.88), and definite/probable stent thrombosis (ZES 2.8% 
versus EES 1.8%, P=0.12).
Conclusions—At 5-year follow-up, ZES and EES had similar efficacy and safety in a population of patients who had 
minimal exclusion criteria.
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along with improved stent design and thinner struts.12 These 
newer stents have shown promising results and improved 
clinical outcomes compared with first-generation DES13,14; 
however, the long-term data on direct comparison between the 
newer-generation DES is scarce.
The RESOLUTE all-comers (Randomized Comparison of 
a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent 
for Percutaneous Coronary Intervention) trial aimed to com-
pare the Resolute zotarolimus-eluting stent (ZES; Medtronic 
CardioVascular Ltd) and Xience-V everolimus-eluting stent 
(EES; Abbott Vascular Ltd).13 It has been shown that ZES was 
noninferior to the EES with respect to the primary end point 
of target lesion failure at 12 months, which occurred in 8.2% 
and 8.3% of patients, respectively (P<0.001 for noninferiority). 
There were no significant between-group differences in the rate 
of death from cardiac causes, any myocardial infarction, repeat 
revascularization, or stent thrombosis at 12 months.We report 
the clinical outcomes at the final 5-year follow-up of this trial.
Methods
The study complies with the Declaration of Helsinki. Study protocol 
was approved by the relevant ethics committees and informed con-
sent was obtained from all participants (or their guardians).
Study Design and Population
The study design of the RESOLUTE all-comers trial has previously 
been described13 and is outlined in Figure 1. Briefly, the RESOLUTE 
all-comers trial is a multicentre prospective double-arm randomized 
controlled noninferiority trial. From April 30, 2008, to October 28, 
WHAT IS KNOWN
฀•฀฀Newer-generation drug-eluting stents are superior to 
first-generation drug-eluting stents.
฀•฀฀Data comparing long-term safety and efficacy of 
the second-generation zotarolimus- and everolimus-
eluting stents are limited.
WHAT THE STUDY ADDS
฀•฀฀RESOLUTE all-comer prospective, multicentre, 
randomized, 2-arm, open-label, noninferiority trial 
randomized 2292 patients to treatment with either 
zotarolimus- or everolimus-eluting stents and fol-
lowed them for 5 years.
฀•฀฀At 5 years, there were no differences in patient-ori-
ented composite end point, device-oriented composite 
end point, major adverse cardiovascular events, and 
definite/probable stent thrombosis between zotaroli-
mus- or everolimus-eluting stents–treated patients.
Figure 1. Flow diagram of RESOLUTE all-comers 
trial. RESOLUTE indicates Randomized Compari-
son of a Zotarolimus-Eluting Stent With an Evero-
limus-Eluting Stent for Percutaneous Coronary 
Intervention.
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2008, we recruited 2292 adult patients with chronic, stable coronary 
artery disease or acute coronary syndromes, including myocardial 
infarction with or without ST-segment–elevation. The trial was pow-
ered for noninferiority testing of the primary end point at 12 months 
on an intention-to-treat basis; the details of power calculation have 
been described previously.13 Patients were randomly assigned to un-
dergo percutaneous coronary intervention with either ZES or EES. 
Patients were eligible if they had at least one coronary lesion with 
percentage diameter stenosis >50% in a vessel with a reference diam-
eter of 2.25 to 4.0 mm. There were minimal exclusion criteria and no 
restrictions on total number of treated lesions, treated vessels, lesion 
length, or number of stents implanted.
Study Procedure
Procedures were performed according to standard techniques with 
the aim to treat all coronary lesions in one session; however, staged 
procedures within 6 weeks were permitted. Mixture of different DES 
types was prohibited unless the operator was unable to insert the 
study stent. Procedural anticoagulation was achieved with unfrac-
tionated heparin at a dose of 5000 IU or 70 to 100 IU per kilogram of 
body weight to maintain an activated clotting time of >250 seconds; 
the use of glycoprotein IIb/IIIa inhibitors was at the operators’ dis-
cretion. All patients received at least 75 mg of acetylsalicylic acid 
before the procedure. A loading dose of 300 to 600 mg of clopidogrel 
was administered if the patient had received no clopidogrel during the 
previous 7 days. All patients were discharged with a prescription of at 
least 75 mg of acetylsalicylic acid indefinitely and 75 mg of clopido-
grel for a minimum of 6 months after the index procedure.
Follow-Up and Clinical End Points
Patients were followed-up by telephone call or hospital visit at 1, 6, and 
12 months and yearly thereafter until 5 years. The primary end point of 
the trial was target lesion failure (TLF) defined as the composite of car-
diac death, myocardial infarction (not clearly attributable to a nontarget 
vessel), and target lesion revascularization (clinically indicated) at 12 
months.13 The current article reports the secondary clinical outcomes 
of this trial at final 5-year follow-up. These predefined end points in-
clude device-oriented composite end point or TLF (combination of 
cardiac death, myocardial infarction not clearly attributable to a non-
target vessel, and clinically indicated target lesion revascularization), 
patient-oriented composite end point (combination of all-cause mor-
tality, myocardial infarction, and any revascularizations), target vessel 
failure (combination of cardiac death, myocardial infarction not clearly 
attributable to a nontarget vessel, and clinically indicated target vessel 
revascularization) and major adverse cardiac events (combination of 
all-cause death, all myocardial infarction, emergent coronary bypass 
surgery, or clinically indicated target lesion revascularization). We have 
also presented all the individual end points, as defined previously,13 and 
stent thrombosis as defined by the Academic Research Consortium.15
Statistical Analysis
Categorical variables are presented as counts and percentages and 
compared using Chi-square or Fisher exact test. Continuous variables 
are presented as means±standard deviation and compared using the 
Student’s unpaired t test or 1-way analysis of variance, as appropriate. 
Survival curves were constructed using Kaplan–Meier estimates and 
Table 1. Comparison of Baseline Characteristics Between the Groups Treated With Zotarolimus- and 
Everolimus-Eluting Stents
Patient Characteristics
Resolute (ZES)  
(N=1140 Patients)
Xience-V (EES)  
(N=1152 Patients) Difference [95% CI] P Value
Age, y 64.4±10.9 64.2±10.8 0.2 [−0.7, 1.1] 0.67
BMI, kg/m² 27.8±4.4 27.8±4.3 0.1 [−0.3, 0.4] 0.68
Male 76.6% 77.2% −0.6% [−4.0, 2.9] 0.77
Prior MI 28.8% 30.4% −1.7% [−5.4, 2.1] 0.41
Prior PCI 31.8% 32.1% −0.3% [−4.1, 3.5] 0.89
Current smoker 26.5% 26.5% 0.0% [−3.6, 3.6] 1.00
Hyperlipidemia 64.0% 67.7% −3.7% [−7.6, 0.2] 0.064
Diabetes mellitus 23.5% 23.4% 0.1% [−3.4, 3.5] 1.00
Hypertension 71.1% 71.3% −0.1% [−3.8, 3.6] 0.96
Prior CABG 10.0% 9.5% 0.5% [−2.0, 2.9] 0.73
Revascularization for AMI 34.5% 33.7% 0.8% [−3.1, 4.7] 0.69
Serum creatinine, μmol/L 87.2±50.6 85.7±37.2 1.6 [−2.1, 5.2] 0.41
Syntax score 14.8±9.3 14.6±9.2 0.2 [−0.6, 1.0] 0.60
Procedural characteristics
  Prestent balloon dilatation 69.5% 70.2% −0.7% [−4.5, 3.1] 0.75
  Maximum balloon pressure, atm 15.60±3.03 15.87±3.18 −0.27 [−0.53, −0.01] 0.038
  Duration of procedure, min 45.01±31.32 43.31±28.34 1.70 [−0.74, 4.15] 0.17
  Fluoroscopy time, min 14.76±14.1 14.05±11.0 0.71 [−0.35, 1.76] 0.19
  Total contrast, mL 233.2±110.3 230.9±104.0 2.3 [−6.5, 11.1] 0.61
  Duration of hospitalization, days 2.74±3.59 2.79±3.66 −0.05 [−0.35, 0.24] 0.72
  Number of treated lesions 1.46±0.73 1.48±0.77 −0.02 [−0.08, 0.04] 0.46
  Staged PCI 8.2% 9.2% −1.0% [−3.3, 1.3] 0.42
  Total stent length per patient, mm 34.42±24.49 36.98±26.49 −2.56 [−4.65, −0.47] 0.016
  Number of stents per patient 1.90±1.21 2.02±1.34 −0.12 [−0.23, −0.02] 0.021
BMI indicates body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; EES, everolimus-eluting stents; MI, 
myocardial infarction; PCI, percutaneous coronary intervention; RESOLUTE, Randomized Comparison of a Zotarolimus-Eluting Stent 
With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention; and ZES, zotarolimus-eluting stents.
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compared using log-rank test. A 2-tailed P value of <0.05 was con-
sidered to indicate statistical significance. Statistical analyses were 
performed using SAS version 9.2 (SAS Institute, Inc, Cary).
Results
A total of 2292 patients were enrolled and randomly assigned 
to treatment with ZES (n=1140) or EES (n=1152). The 2 
groups were well-matched for the baseline demographical, 
clinical, and angiographic characteristics, except for difference 
in number of stents used, total length of stents used, and the 
maximum balloon pressure (Table 1), as previously reported.13 
The mean age was 64±11 years, with 77% males and 23% dia-
betics in both groups. There were ≈34% patients in both study 
arms who underwent revascularization for acute myocardial 
infarction. The mean SYNTAX score was also similar in both 
groups (ZES 14.8±9.3 versus EES 14.6±9.2, P=0.63).
Follow-up data at 5 years were available for 98% patients. 
There was no difference in usage of dual antiplatelet therapy 
between the 2 groups at 30 day (ZES 93.9% versus EES 
94.3%, P=0.72), 1 year (ZES 84.2% versus 83.3%, P=0.61), 
2 year (ZES 17.8% versus 18.2%, P=0.82), and 5 year (ZES 
11.0% versus EES 10.9%, P=0.94).
At 5-year follow-up, there were no differences in the 
incidence of patient-oriented (ZES 35.3% versus EES 
32.0%, P=0.11) or device-oriented (ZES 17.0% versus EES 
16.2%, P=0.61) end points between the 2 groups (Figure 2). 
Furthermore, we noted no differences between the 2 stent 
groups for major adverse cardiac events (ZES 21.9% versus 
EES 21.6%, P=0.88) and target vessel failure (ZES 20.0% 
versus EES 19.1%, P=0.60) at the final follow-up (Figure 2). 
The 2 groups also had no difference in other clinical end 
points, including death, cardiac death, myocardial infarction, 
revascularization, and stent thrombosis (Table 2). The detailed 
incidence of stent thrombosis in the 2 groups during 5-year 
follow-up period is provided in Table in the Data Supplement.
Stratified analysis of the primary end point (device-ori-
ented composite end point/TLF) at 5 years across different 
patient subgroups (including diabetics and acute coronary 
syndromes) and anatomic complexity of coronary artery dis-
ease revealed no difference in outcomes between ZES- and 
EES-treated patients (Figure 3).
Discussion
The RESOLUTE all-comers trial directly compared the 
performance of 2 newer-generation stents in an all-comers 
population over a long follow-up period. The main finding 
of the present study is that at 5-year follow-up, ZES and EES 
were similar in clinical efficacy and safety with no difference 
Figure 2. Kaplan–Meier curves comparing zotarolimus- and everolimus-eluting stents for clinical end points. Zotarolimus- and everlo-
mius-eluting stents had similar patient-oriented composite end point (PoCE; combination of all-cause mortality, myocardial infarction, 
and any revascularization; A), device-oriented composite end point (DoCE; combination of cardiac death, myocardial infarction not clearly 
attributable to a nontarget vessel, and clinically indicated target lesion revascularization; B), target vessel failure (TVF; combination of car-
diac death, myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target vessel revascularization; C), 
and major adverse cardiac events (MACE; combination of all-cause death, all myocardial infarction, emergent coronary bypass surgery, 
or clinically indicated target lesion revascularization; D). Error bars indicate a point-wise 2-sided 95% confidence interval (1.96 SD). Stan-
dard error based on the Greenwood Formula.
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Table 2. All Clinical End Points at 5-Year Follow-Up
End Point
Resolute (ZES)  
(N=1140 Patients)
Xience-V (EES)  
(N=1152 Patients) Difference [95% CI] P Value
PoCE 35.3% (396/1123) 32.0% (363/1133) 3.2% [−0.7%, 7.1%] 0.11
DoCE/TLF 17.0% (191/1123) 16.2% (183/1133) 0.9% [−2.2%, 3.9%] 0.61
TVF 20.0% (225/1123) 19.1% (216/1133) 1.0% [−2.3%, 4.2%] 0.60
MACE 21.9% (246/1123) 21.6% (245/1133) 0.3% [−3.1%, 3.7%] 0.88
Death 11.0% (123/1123) 10.8% (122/1133) 0.2% [−2.4%, 2.8%] 0.89
  Cardiac death 6.5% (73/1123) 5.7% (65/1133) 0.8% [−1.2%, 2.7%] 0.48
  Vascular death 0.8% (9/1123) 1.0% (11/1133) −0.2% [−0.9%, 0.6%] 0.82
  Noncardiovascular death 3.7% (41/1123) 4.1% (46/1133) −0.4% [−2.0%, 1.2%] 0.66
All MI (extended historical definition) 7.1% (80/1123) 6.8% (77/1133) 0.3% [−1.8%, 2.4%] 0.80
  Q wave 1.9% (21/1123) 1.1% (13/1133) 0.7% [−0.3%, 1.7%] 0.17
  Non-Q wave 5.6% (63/1123) 5.6% (64/1133) −0.0% [−1.9%, 1.9%] 1.00
TV MI in target vessel (extended 
historical definition)
5.7% (64/1123) 5.7% (65/1133) −0.0% [−2.0%, 1.9%] 1.00
  Q wave 1.3% (15/1123) 0.8% (9/1133) 0.5% [−0.3%, 1.4%] 0.23
  Non-Q wave 4.6% (52/1123) 4.9% (56/1133) −0.3% [−2.1%, 1.4%] 0.77
All MI (ARC defined) 18.0% (202/1123) 16.5% (187/1133) 1.5% [−1.6%, 4.6%] 0.37
  Q wave 1.9% (21/1123) 1.1% (12/1133) 0.8% [−0.2%, 1.8%] 0.12
  Non-Q wave 16.7% (188/1123) 15.5% (176/1133) 1.2% [−1.8%, 4.2%] 0.46
MI in target vessel (ARC defined) 16.0% (180/1123) 15.0% (170/1133) 1.0% [−2.0%, 4.0%] 0.52
  Q wave 1.3% (15/1123) 0.7% (8/1133) 0.6% [−0.2%, 1.5%] 0.15
  Non-Q wave 15.0% (169/1123) 14.3% (162/1133) 0.8% [−2.2%, 3.7%] 0.63
All revascularizations 24.0% (270/1123) 20.7% (234/1133) 3.4% [−0.0%, 6.8%] 0.055
  CABG 3.6% (40/1123) 2.9% (33/1133) 0.6% [−0.8%, 2.1%] 0.41
  RePCI 21.6% (243/1123) 18.4% (209/1133) 3.2% [−0.1%, 6.5%] 0.059
TLR 10.2% (114/1123) 8.9% (101/1133) 1.2% [−1.2%, 3.7%] 0.35
  CABG 1.9% (21/1123) 1.6% (18/1133) 0.3% [−0.8%, 1.4%] 0.63
  RePCI 8.8% (99/1123) 7.6% (86/1133) 1.2% [−1.0%, 3.5%] 0.32
Clinically driven TLR 7.8% (88/1123) 7.1% (81/1133) 0.7% [−1.5%, 2.9%] 0.58
  CABG 1.4% (16/1123) 1.4% (16/1133) 0.0% [−1.0%, 1.0%] 1.00
  RePCI 6.9% (77/1123) 6.0% (68/1133) 0.9% [−1.2%, 2.9%] 0.44
TVR 14.9% (167/1123) 13.4% (152/1133) 1.5% [−1.4%, 4.3%] 0.33
  CABG 2.5% (28/1123) 2.3% (26/1133) 0.2% [−1.1%, 1.5%] 0.78
  RePCI 13.1% (147/1123) 11.7% (132/1133) 1.4% [−1.3%, 4.2%] 0.31
Clinically driven TVR 11.4% (128/1123) 10.9% (123/1133) 0.5% [−2.1%, 3.1%] 0.69
  CABG 1.9% (21/1123) 1.9% (22/1133) −0.1% [−1.2%, 1.1%] 1.00
  RePCI 10.1% (113/1123) 9.4% (106/1133) 0.7% [−1.7%, 3.2%] 0.62
Target lesion–related stent thrombosis
  Definite 1.6% (18/1123) 0.8% (9/1133) 0.8% [−0.1%, 1.7%] 0.084
  Definite+probable 2.4% (27/1123) 1.7% (19/1133) 0.7% [−0.4%, 1.9%] 0.24
  Definite+probable+possible 6.8% (76/1123) 5.4% (61/1133) 1.4% [−0.6%, 3.4%] 0.19
All events were adjudicated by the independent clinical event committee. Extended historical definition of MI is used for all the 
composite end points.
PoCE included combination of all-cause mortality, myocardial infarction, and any revascularization; DoCE or TLF included 
combination of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel, and clinically indicated target lesion 
revascularization; TVF included combination of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel, and 
clinically indicated target vessel revascularization; MACE included combination of all-cause death, all myocardial infarction, emergent 
coronary bypass surgery, or clinically indicated target lesion revascularization.
ARC indicates academic research consortium; CABG, coronary artery bypass grafting; CI, confidence interval; DoCE, device-oriented 
composite end point; EES, everolimus-eluting stents; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; PoCE, patient-oriented composite end point; RESOLUTE, Randomized Comparison of a Zotarolimus-Eluting Stent 
With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention; TLF, target lesion failure; TLR, target lesion revascularization; 
TVF, target vessel failure; TVR, target vessel revascularization; and ZES, zotarolimus-eluting stents.
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in either patient-oriented and device-oriented end points or 
stent thrombosis.
The DES are the main stay in treating patients with flow-
limiting coronary lesions.16,17 First-generation DES showed a 
substantial improvement reduction in restenosis and need for 
repeat revascularization compared with bare metal stents.6,7 
However, these first-generation devices failed in adding 
a major gain in terms of long-term mortality18 and a major 
concern remained on long-term safety, in particular, related 
to late stent thrombosis.8,9,19–24 The second-generation DES, 
with novel stent design/material, improved polymer biocom-
patibility, and novel antiproliferative drugs were developed to 
improve acute performance and long-term outcomes.11,14
ZES and EES have previously been shown to be equiva-
lent in terms of procedural success, angiographic late lumen 
loss, and short-/midterm clinical outcomes.13,25,26 Our data 
confirms that they remain comparable over a long follow-up 
period of 5 years. These results are consistent with reports 
from other trials and registries.27,28 The Real-World Endeavor 
Resolute Versus Xience V Drug-Eluting Stent Study in 
Twente (TWENTE) trial randomly assigned patients to ZES 
(n=697) or EES (n=694) and found no difference in patient-
oriented composite end point (ZES 16.4% versus EES 17.1%, 
P=0.75) and target vessel failure (ZES 10.8% versus EES 
11.6, P=0.65) at 2-year follow-up.27 It has also been shown 
that there is no difference in outcomes between the 2 stents 
when used for patients with complex coronary disease,29,30 
long lesions requiring overlapping stents,31 unprotected left 
main stem,32 small diameter (<2.7 mm) vessels,33 and bifurca-
tion lesions.34 Our findings from stratified analyses corrobo-
rate these studies.
The incidence of stent thrombosis in ZES- or EES-treated 
patients in this study was similar and comparable to other 
studies. In the LEADERS trial, the incidence of definite/prob-
able stent thrombosis at 5 year for second-generation biolimus 
eluting stent was 3.6%. In the TWENTE trial, 95% patients 
were asked to discontinue dual antiplatelet therapy after 12 
months. Two-year rates of definite or probable stent thrombo-
sis were similar (ZES 1.2% versus EES 1.4%, P=0.63).27
ZES (cobalt-chromium platform) has been reported to be 
equivalent to the newer platinum-chromium (Pt-Cr)– based 
EES (Promus Element, Boston Scientific Ltd),35,36 whereas 
Pt-Cr–based (Promus Element) and cobalt-chromium–based 
(Xience-V) EES are also comparable in outcomes.37 HOST-
ASSURE trial randomized 3755 all-comer patients undergo-
ing percutaneous coronary intervention to PtCr-EES or ZES. 
At 1-year, the primary end point of TLF occurred in 2.9% 
and 2.9% of the population in the PtCr-EES and ZES groups, 
respectively (superiority P=0.98, noninferiority P=0.025). 
There were no significant differences in the individual com-
ponents of TLF, as well as the patient-oriented clinical out-
come.35 Another recently reported all-comer trial (n=1811 
patients) comparing cobalt-chromium–based ZES (n=906) 
against Promus Element (Pt-Cr EES, n=905) has shown no 
difference in the primary end point of target vessel failure 
or its individual components at 12-month follow-up. There 
was also no difference in stent thrombosis (ZES 0.3% versus 
Promus Element 0.7%, P=0.34).36 There was also no differ-
ence in the outcomes for patients presenting with ST-elevation 
myocardial infarction.36
Limitations
This study’s powered primary end point was target lesion 
failure at 1 year, and the clinical outcome at the final 5-year 
follow-up is a secondary end point. However, it was a pre-
specified secondary end point, with all events adjudicated by 
an independent Clinical Events Committee.
Conclusions
ZES and EES offered similar patient- and device-related end 
points at 5-year follow-up. Both ZES and EES are the most 
widely used DES at the moment, and our results indeed con-
firm that these stents have equally good outcomes during a 
long-term follow-up.
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Figure 3. Forest plot showing prespecified subgroups analysis comparing zotarolimus- and everolimus-eluting stents for target lesion 
failure at 5-year follow-up. Zotarolimus- and everolimus-eluting stents had similar device-oriented composite end point (DoCE) or target 
lesion failure (TLF), including combination of cardiac death, myocardial infarction (MI) not clearly attributable to a nontarget vessel, and 
clinically indicated target lesion revascularization. Error bars indicate a point-wise 2-sided 95% confidence interval (1.96 SD). Standard 
error based on the Greenwood Formula. EES indicates everolimus-eluting stents; and ZES, zotarolimus-eluting stents.
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